Edmond DE Rothschild Holding S.A. Reduces Position in DexCom, Inc. (NASDAQ:DXCM)

Edmond DE Rothschild Holding S.A. trimmed its stake in DexCom, Inc. (NASDAQ:DXCM) by 99.7% in the fourth quarter, HoldingsChannel.com reports. The fund owned 3,515 shares of the medical device company’s stock after selling 1,204,600 shares during the quarter. Edmond DE Rothschild Holding S.A.’s holdings in DexCom were worth $273,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also made changes to their positions in DXCM. Forvis Mazars Wealth Advisors LLC lifted its holdings in DexCom by 0.7% in the 4th quarter. Forvis Mazars Wealth Advisors LLC now owns 17,481 shares of the medical device company’s stock valued at $1,359,000 after purchasing an additional 118 shares in the last quarter. Principal Securities Inc. raised its position in shares of DexCom by 3.4% in the fourth quarter. Principal Securities Inc. now owns 4,069 shares of the medical device company’s stock valued at $316,000 after buying an additional 135 shares during the last quarter. Larson Financial Group LLC lifted its stake in shares of DexCom by 40.5% during the fourth quarter. Larson Financial Group LLC now owns 475 shares of the medical device company’s stock valued at $37,000 after buying an additional 137 shares during the period. Level Four Advisory Services LLC boosted its position in DexCom by 1.1% during the fourth quarter. Level Four Advisory Services LLC now owns 13,196 shares of the medical device company’s stock worth $1,026,000 after acquiring an additional 150 shares during the last quarter. Finally, TD Private Client Wealth LLC grew its stake in DexCom by 62.8% in the 4th quarter. TD Private Client Wealth LLC now owns 433 shares of the medical device company’s stock worth $34,000 after acquiring an additional 167 shares during the period. 97.75% of the stock is currently owned by hedge funds and other institutional investors.

DexCom Stock Performance

Shares of DXCM opened at $68.14 on Thursday. The firm has a fifty day moving average of $81.24 and a 200-day moving average of $77.04. The company has a market cap of $26.63 billion, a price-to-earnings ratio of 47.65, a price-to-earnings-growth ratio of 2.30 and a beta of 1.28. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.28 and a current ratio of 1.47. DexCom, Inc. has a 1 year low of $62.34 and a 1 year high of $141.99.

DexCom (NASDAQ:DXCM) last posted its earnings results on Thursday, February 13th. The medical device company reported $0.45 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.50 by ($0.05). DexCom had a net margin of 14.29% and a return on equity of 30.14%. As a group, equities analysts anticipate that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analyst Weigh In

DXCM has been the topic of a number of recent analyst reports. Canaccord Genuity Group increased their price target on DexCom from $99.00 to $103.00 and gave the stock a “buy” rating in a research note on Friday, February 14th. Citigroup raised their price target on DexCom from $101.00 to $104.00 and gave the stock a “buy” rating in a research note on Tuesday, March 4th. Wells Fargo & Company reaffirmed an “overweight” rating on shares of DexCom in a research note on Saturday, March 8th. Baird R W raised shares of DexCom from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 16th. Finally, Redburn Atlantic raised shares of DexCom from a “neutral” rating to a “buy” rating and upped their price target for the stock from $85.00 to $115.00 in a research report on Monday, February 3rd. Five research analysts have rated the stock with a hold rating, thirteen have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, DexCom presently has an average rating of “Moderate Buy” and an average target price of $99.82.

Insider Buying and Selling

In related news, COO Jacob Steven Leach sold 14,076 shares of the company’s stock in a transaction dated Wednesday, March 12th. The shares were sold at an average price of $70.38, for a total value of $990,668.88. Following the completion of the sale, the chief operating officer now owns 313,497 shares of the company’s stock, valued at $22,063,918.86. This represents a 4.30 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Kevin R. Sayer sold 33,359 shares of the firm’s stock in a transaction dated Wednesday, January 29th. The shares were sold at an average price of $86.91, for a total transaction of $2,899,230.69. Following the transaction, the chief executive officer now directly owns 319,037 shares in the company, valued at approximately $27,727,505.67. The trade was a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 105,009 shares of company stock valued at $8,044,178 in the last three months. 0.30% of the stock is currently owned by corporate insiders.

DexCom Company Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.